Business
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights. "This past year w
About this update from Serina Therapeutics, Inc.
[{"type":"image","alt":"Serina Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Serina Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":88,"url":"https://media.zenfs.com/en/globenewswire.com/339c0b6f27c396eb444a95862a9f2125"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MJppK4jjv3tw7HeGbiFD_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMw--/https://media.zenfs.com/en/globenewswire.com/339c0b6f27c396eb444a95862a9f2125","width":300,"height":88}},"lazy":false},{"type":"text","content":"- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million","length":131,"tagName":"p"},{"type":"text","content":"HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights.","length":367,"tagName":"p"},{"type":"text","content":""This past year was defined by execution, advancing SER-252 from IND filing through FDA clearance, into the clinic while strengthening our balance sheet to support the clinical milestones ahead," said Steve Ledger, CEO of Serina. "With the first patient dosed in our registrational trial in advanced Parkinson's disease, and up to $30 million in new financing now secured, Serina enters 2026 with the clinical and financial foundation to reach meaningful value-creating inflection points. We are grateful to Dr. Greg Bailey for leading this financing and stepping into the role of Co-Chairman alongside Dr. Simba Gill. His commitment to SER-252 and the broader POZ platform opportunity and extensive experience guiding biotechnology companies make him an exceptional partner as we advance this program."","length":827,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"FDA Grants IND Clearance for SER-252; Phase 1b Trial Initiated: In January 2026, Serina announced the U.S. Food and Drug Administration (FDA) had cleared the Investigational New Drug (IND) application for its lead product, SER-252, for the tre...